Plus   Neg

Amgen Launches AMGEVIT In Markets Across Europe - Quick Facts

Amgen (AMGN) announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018.

AMGEVITA specified that it is the first adalimumab biosimilar to be approved by the European Commission (EC).

AMGEVITA is authorized for treatment of inflammatory diseases in adults and for pediatric inflammatory diseases.

Amgen has a total of 10 biosimilars in its portfolio, three of which have been approved by the EC. AMGEVITA will launch in the 28 countries that are members of the European Union as well as in Norway, Iceland and Liechtenstein, which are members of the European Economic Area.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT